<DOC>
	<DOCNO>NCT02292472</DOCNO>
	<brief_summary>This study design A Randomized , Double-blind , Multi-center , Phase II Optimal Dose-finding Study Determine Safety Efficacy Meditoxin® Subjects Benign Masseteric Hypertrophy .</brief_summary>
	<brief_title>Medytoxin® Treatment Patients With Benign Masseteric Hypertrophy</brief_title>
	<detailed_description>Subjects voluntarily sign informed consent judge eligible study intramuscularly inject study drug placebo find appropreate dose treatment Benign Masseteric Hypertrophy . Thereafter , follow-up visit make efficacy safety assessment conduct .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Subject show benign masseteric hypertrophy 2 . Male female subject 19 year age write informed consent obtain patient LAR . 3 . Subject bisymmetry masster visual assessment . 4 . Subejects qualify standard meet ultrasonics wave value . 5 . Subjects comply requirement protocol . 1 . Diagnosis myasthenia , facial palsy severe facial asymmetry 2 . Subject get treatment , include double jaw surgery , laser , thread treatment etc . 1 year . 3 . Subject previously receive botulinum toxin within 3 month prior study entry 4 . Subject participate investigational study present 30 prior screen date . 5 . Subject know hypersensitivity botulinum toxin 6 . Subject pregnant lactating find pregnancy though urine sebum test disagree avoid pregnancy study preiod . 7 . Subjects eligible study discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>masticatory muscle</keyword>
</DOC>